BCL2 and acute myeloid leukemia: We demonstrated that nanovehicles developed from phenylboronic acid‐functionalized polypeptides could enable nearly quantitative coencapsulation and triggered release of both BCL2 and MCL1 inhibitors for synergetic and potent therapy of AML.